Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

IBRANCE Drug Profile

« Back to Dashboard

Which patents cover Ibrance, and what substitute generic drugs are available?

Ibrance is a drug marketed by Pfizer Inc and is included in one NDA. There are three patents protecting this drug.

This drug has sixty patent family members in forty-four countries.

The generic ingredient in IBRANCE is palbociclib. Two suppliers are listed for this compound. Additional details are available on the palbociclib profile page.

Summary for Tradename: IBRANCE

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list62
Clinical Trials: see list31
Patent Applications: see list52
Drug Prices:see details
DailyMed Link:IBRANCE at DailyMed

Pharmacology for Tradename: IBRANCE

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-001Feb 3, 2015RXYesNo7,456,168► Subscribe ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-003Feb 3, 2015RXYesYes► Subscribe► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-002Feb 3, 2015RXYesNo7,456,168► Subscribe ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-001Feb 3, 2015RXYesNo7,208,489► SubscribeYY ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-002Feb 3, 2015RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: IBRANCE

Country Document Number Estimated Expiration
South Korea20060111716► Subscribe
Dominican RepublicP2003000561► Subscribe
Poland220952► Subscribe
MexicoPA04005939► Subscribe
Costa Rica20120129► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc